Citigroup
GRCE

Citigroup’s Grace Therapeutics GRCE Stock Holding History

Citigroup’s Portfolio GRCE Stock Details GRCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,757
Closed -$8.19K – 6586
2025
Q3 		$8.19K Buy
2,757
+2,756
+275,600% +$8.64K ﹤0.01% 5081
2025
Q2 		$3 Buy
+1
New +$3 ﹤0.01% 5605
2016
Q2 		– Sell
-5
Closed – – 7490
2016
Q1 		$0 Buy
5
+4
+400% +$313 ﹤0.01% 7812
2015
Q4 		$0 Buy
+1
New +$118 ﹤0.01% 7912
2015
Q3 		– Sell
-1
Closed – – 7765
2015
Q2 		$0 Buy
+1
New +$186 ﹤0.01% 7792
2015
Q1 		– Sell
-3
Closed -$1K – 7476
2014
Q4 		$1K Buy
3
+2
+200% +$492 ﹤0.01% 7004
2014
Q3 		$0 Sell
1
-16
-94% -$7.52K ﹤0.01% 7340
2014
Q2 		$8K Sell
17
-4
-19% -$1.91K ﹤0.01% 6275
2014
Q1 		$12K Buy
+21
New +$12.8K ﹤0.01% 6268

Other funds holding GRCE

NCM
Nantahala Capital Management New Canaan, Connecticut $3B AUM 119.43% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Cerity Partners
Cerity Partners New York $82.7B AUM 28.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Citigroup's GRCE Position: Q4 2025 in Review

Citigroup sold out of Grace Therapeutics (GRCE) in Q4 2025, closing a stake of 2,757 shares — an estimated $8.19K sold.

Citigroup first reported a position in GRCE in Q1 2014 and held it in 9 quarters. The position peaked at $12K in Q1 2014. 23 funds tracked by Wall St. Rank hold GRCE as of Q4 2025.

  • Citigroup reported no remaining Grace Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Citigroup sold 2,757 Grace Therapeutics shares in Q4 2025, an estimated $8.19K.
  • Citigroup first reported a position in Grace Therapeutics in Q1 2014 and held it in 9 quarters.
  • Citigroup's Grace Therapeutics position peaked at $12K in Q1 2014.
  • 23 funds tracked by Wall St. Rank held Grace Therapeutics as of Q4 2025.

Based on Citigroup's 13F filing for Q4 2025, filed 13 Feb 2026.